ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2020355 citationsJournal Article

Authors

Acalabrutinib significantly improved PFS compared with I-R or B-R and has an acceptable safety profile in patients with R/R CLL.

Published in: Journal of Clinical Oncology

Volume 38, Issue 25, pp. 2849-2861

Field-Weighted Citation Impact: 31.10